<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="/resources/spdi-openaccess-jats.xsl"?>
<!DOCTYPE response [
	
<!ENTITY % article SYSTEM "http://jats.nlm.nih.gov/archiving/1.2/JATS-archivearticle1.dtd">
<!ENTITY % book-part-wrapper SYSTEM "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
	]><response><apiMessage>This XML was provided by Springer Nature</apiMessage><query>doi:10.1186/s12879-019-4270-2</query><apiKey>6b19ee21fe6a243741a528650f7c8997</apiKey><result><total>1</total><start>1</start><pageLength>1</pageLength><recordsDisplayed>1</recordsDisplayed></result><records><article dtd-version="1.2" article-type="research-article" xml:lang="en" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><?properties open_access?><front><journal-meta><journal-id journal-id-type="publisher-id">12879</journal-id><journal-title-group><journal-title>BMC Infectious Diseases</journal-title><abbrev-journal-title abbrev-type="publisher">BMC Infect Dis</abbrev-journal-title></journal-title-group><issn pub-type="epub">1471-2334</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">s12879-019-4270-2</article-id><article-id pub-id-type="manuscript">4270</article-id><article-id pub-id-type="doi">10.1186/s12879-019-4270-2</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="article-collection" specific-use="SubjectSection"><subject>Hepatitis and co-infections</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Hepatitis C virus infection status and associated factors among a multi-site sample of people who used illicit drugs in the Amazon region</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="Au1"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-4888-3530</contrib-id><name><surname>Oliveira-Filho</surname><given-names>Aldemir B.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="corresp" rid="IDs1287901942702_cor1">a</xref></contrib><contrib contrib-type="author" id="Au2"><name><surname>Santos</surname><given-names>Francisco Junior A.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" id="Au3"><name><surname>Silva</surname><given-names>Fabricio Quaresma</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" id="Au4"><name><surname>Raiol</surname><given-names>Nairis Costa</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" id="Au5"><name><surname>Costa</surname><given-names>Camila Carla S.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" id="Au6"><name><surname>Piauiense</surname><given-names>Juliana Nadia F.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" id="Au7"><name><surname>Martins</surname><given-names>Luisa Caricio</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" id="Au8"><name><surname>Cardoso</surname><given-names>Yasmin Maria N.</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author" id="Au9"><name><surname>Di Miceli</surname><given-names>Jeruza Ferraz F.</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author" id="Au10"><name><surname>Resque</surname><given-names>Rafael Lima</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author" id="Au11"><name><surname>Silva-Oliveira</surname><given-names>Gláucia C.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" id="Au12"><name><surname>Pinheiro</surname><given-names>Luiz Marcelo L.</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author" id="Au13"><name><surname>Machado</surname><given-names>Luiz Fernando A.</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author" id="Au14"><name><surname>Pinho</surname><given-names>João Renato R.</given-names></name><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author" id="Au15"><name><surname>Lemos</surname><given-names>José Alexandre R.</given-names></name><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author" id="Au16"><name><surname>Kupek</surname><given-names>Emil</given-names></name><xref ref-type="aff" rid="Aff8">8</xref></contrib><contrib contrib-type="author" id="Au17"><name><surname>Fischer</surname><given-names>Benedikt</given-names></name><xref ref-type="aff" rid="Aff9">9</xref><xref ref-type="aff" rid="Aff10">10</xref><xref ref-type="aff" rid="Aff11">11</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2171 5249</institution-id><institution-id institution-id-type="GRID">grid.271300.7</institution-id><institution content-type="org-division">Laboratório de Células e Patógenos, Grupo de Estudo e Pesquisa em Populações Vulneráveis (GEPPOV), Instituto de Estudos Costeiros, Campus de Bragança</institution><institution content-type="org-name">Universidade Federal do Pará</institution></institution-wrap><addr-line content-type="street">Alameda Leandro Ribeiro, s/n. Aldeia</addr-line><addr-line content-type="city">Bragança</addr-line><addr-line content-type="state">PA</addr-line><country country="BR">Brazil</country></aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2171 5249</institution-id><institution-id institution-id-type="GRID">grid.271300.7</institution-id><institution content-type="org-division">Laboratório de Patologia Clínica de Doenças Tropicais, Núcleo de Medicina Tropical</institution><institution content-type="org-name">Universidade Federal do Pará</institution></institution-wrap><addr-line content-type="city">Belém</addr-line><addr-line content-type="state">PA</addr-line><country country="BR">Brazil</country></aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0643 9014</institution-id><institution-id institution-id-type="GRID">grid.440559.9</institution-id><institution content-type="org-division">Laboratório de Toxicologia e Química Farmacêutica, Centro de Ciências Biológicas e da Saúde</institution><institution content-type="org-name">Universidade Federal do Amapá</institution></institution-wrap><addr-line content-type="city">Macapá</addr-line><addr-line content-type="state">AP</addr-line><country country="BR">Brazil</country></aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2171 5249</institution-id><institution-id institution-id-type="GRID">grid.271300.7</institution-id><institution content-type="org-division">Faculdade de Ciências Biológicas, Campus do Marajó – Soure</institution><institution content-type="org-name">Universidade Federal do Pará</institution></institution-wrap><addr-line content-type="city">Soure</addr-line><addr-line content-type="state">PA</addr-line><country country="BR">Brazil</country></aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2171 5249</institution-id><institution-id institution-id-type="GRID">grid.271300.7</institution-id><institution content-type="org-division">Laboratório de Virologia, Instituto de Ciências Biológicas</institution><institution content-type="org-name">Universidade Federal do Pará</institution></institution-wrap><addr-line content-type="city">Belém</addr-line><addr-line content-type="state">PA</addr-line><country country="BR">Brazil</country></aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1937 0722</institution-id><institution-id institution-id-type="GRID">grid.11899.38</institution-id><institution content-type="org-division">Laboratório de Gastroenterologia e Hepatologia, Instituto de Medicina Tropical</institution><institution content-type="org-name">Universidade de São Paulo</institution></institution-wrap><addr-line content-type="city">São Paulo</addr-line><addr-line content-type="state">SP</addr-line><country country="BR">Brazil</country></aff><aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2171 5249</institution-id><institution-id institution-id-type="GRID">grid.271300.7</institution-id><institution content-type="org-division">Programa de Pós-Graduação Profissional em Análises Clínicas, Instituto de Ciências Biológicas</institution><institution content-type="org-name">Universidade Federal do Pará</institution></institution-wrap><addr-line content-type="city">Belém</addr-line><addr-line content-type="state">PA</addr-line><country country="BR">Brazil</country></aff><aff id="Aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2188 7235</institution-id><institution-id institution-id-type="GRID">grid.411237.2</institution-id><institution content-type="org-division">Departamento de Saúde Pública</institution><institution content-type="org-name">Universidade Federal de Santa Catarina</institution></institution-wrap><addr-line content-type="city">Florianópolis</addr-line><addr-line content-type="state">SC</addr-line><country country="BR">Brazil</country></aff><aff id="Aff9"><label>9</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0000 8793 5925</institution-id><institution-id institution-id-type="GRID">grid.155956.b</institution-id><institution content-type="org-division">Institute for Mental Health Policy Research</institution><institution content-type="org-name">Centre for Addiction and Mental Health (CAMH)</institution></institution-wrap><addr-line content-type="city">Toronto</addr-line><country country="CA">Canada</country></aff><aff id="Aff10"><label>10</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2157 2938</institution-id><institution-id institution-id-type="GRID">grid.17063.33</institution-id><institution content-type="org-division">Department of Psychiatry</institution><institution content-type="org-name">University of Toronto</institution></institution-wrap><addr-line content-type="city">Toronto</addr-line><country country="CA">Canada</country></aff><aff id="Aff11"><label>11</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0372 3343</institution-id><institution-id institution-id-type="GRID">grid.9654.e</institution-id><institution content-type="org-division">Faculty of Medical and Health Sciences</institution><institution content-type="org-name">University of Auckland</institution></institution-wrap><addr-line content-type="city">Grafton</addr-line><addr-line content-type="state">AK</addr-line><country country="NZ">New Zealand</country></aff></contrib-group><author-notes><corresp id="IDs1287901942702_cor1"><label>a</label><phone>+ 55 91 3425 1209</phone><email>olivfilho@ufpa.br</email></corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>17</day><month>7</month><year>2019</year></pub-date><pub-date date-type="collection" publication-format="electronic"><month>12</month><year>2019</year></pub-date><volume>19</volume><issue seq="634">1</issue><elocation-id>634</elocation-id><history><date date-type="registration"><day>10</day><month>7</month><year>2019</year></date><date date-type="received"><day>5</day><month>3</month><year>2019</year></date><date date-type="accepted"><day>10</day><month>7</month><year>2019</year></date><date date-type="online"><day>17</day><month>7</month><year>2019</year></date></history><permissions><copyright-statement>© The Author(s). 2019</copyright-statement><copyright-year>2019</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p><bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link xlink:href="http://creativecommons.org/licenses/by/4.0/" ext-link-type="url">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link xlink:href="http://creativecommons.org/publicdomain/zero/1.0/" ext-link-type="url">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1" xml:lang="en"><title>Abstract</title><sec id="ASec1"><title>Background</title><p id="Par1">Elevated rates of Hepatitis C Virus (HCV) infection have been reported in epidemiological studies with people who used illicit drugs (PWUIDs) in different Brazilian regions. In Brazil’s Amazon region, studies have already identified the common use of illicit drugs among adolescents and the high prevalence of HCV infections among PWUIDs. However, all studies done with PWUIDs were conducted with small samples and within limited geographic coverage. This study determined the prevalence and risk factors for HCV infection in PWUIDs in the Amazon region, northern Brazil, as well as estimating the prevalence and factors associated with the HCV spontaneous clearance (HSC).</p></sec><sec id="ASec2"><title>Methods</title><p id="Par2">This cross-sectional study accessed 1666 PWUIDs from multiple municipalities of the Amazon region. Socio-demographic, economic, drug use and health-related information were collected through interviews. Blood samples collected were tested for the presence of anti-HCV antibodies and RNA-HCV. HCV genotypes were identified by real-time polymerase chain reaction (PCR). Logistic regressions were run to identify factors independently associated with HCV infection status and HSC.</p></sec><sec id="ASec3"><title>Results</title><p id="Par3">In total, 577 (34.6%) featured HCV antibodies, of which 384 (23.1%) had active HCV infection and 193 (11.6%) indicated HSC. Genotypes 1 (80.2%) and 3 (18.8%) were detected. HCV infection status was associated with the length of illicit drug use history, factors related to parenteral and sexual transmission, and factors of socio-economic marginalization leading to potential risk activities for HCV. HSC was associated with the ethnic (including indigenous) background of participants.</p></sec><sec id="ASec4"><title>Conclusions</title><p id="Par4">High levels of HCV infection were detected in PWUIDs. Genotype 1 was predominant. Intense use of illicit drugs, unprotected sexual intercourse, high number of sexual partners and social marginalization were associated with all HCV infection. HSC was associated with origin (Amazonian-born) and non-white (e.g., Black or Indigenous) of PWUIDs. These findings emphasize the need for improve HCV prevention and control services and care for PWUIDs in the Brazilian Amazon region.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>HCV</kwd><kwd>Epidemiology</kwd><kwd>Spontaneous clearance</kwd><kwd>People who used illicit drugs</kwd><kwd>Brazil</kwd><kwd>Amazon</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution>Ministério da Saúde/Secretaria de Vigilância em Saúde (MS/SVS)</institution></institution-wrap></funding-source><award-id award-type="FundRef grant">34621.7480001/13-003</award-id></award-group><award-group><funding-source><institution-wrap><institution>Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPQ)</institution></institution-wrap></funding-source><award-id award-type="FundRef grant">475142/2013-6</award-id></award-group></funding-group><custom-meta-group><custom-meta><meta-name>publisher-imprint-name</meta-name><meta-value>BioMed Central</meta-value></custom-meta><custom-meta><meta-name>volume-issue-count</meta-name><meta-value>1</meta-value></custom-meta><custom-meta><meta-name>issue-article-count</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>issue-toc-levels</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>issue-pricelist-year</meta-name><meta-value>2019</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-holder</meta-name><meta-value>The Author(s)</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-year</meta-name><meta-value>2019</meta-value></custom-meta><custom-meta><meta-name>article-contains-esm</meta-name><meta-value>Yes</meta-value></custom-meta><custom-meta><meta-name>article-numbering-style</meta-name><meta-value>Unnumbered</meta-value></custom-meta><custom-meta><meta-name>article-registration-date-year</meta-name><meta-value>2019</meta-value></custom-meta><custom-meta><meta-name>article-registration-date-month</meta-name><meta-value>7</meta-value></custom-meta><custom-meta><meta-name>article-registration-date-day</meta-name><meta-value>10</meta-value></custom-meta><custom-meta><meta-name>article-toc-levels</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>toc-levels</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>volume-type</meta-name><meta-value>Regular</meta-value></custom-meta><custom-meta><meta-name>journal-product</meta-name><meta-value>ArchiveJournal</meta-value></custom-meta><custom-meta><meta-name>numbering-style</meta-name><meta-value>Unnumbered</meta-value></custom-meta><custom-meta><meta-name>article-grants-type</meta-name><meta-value>OpenChoice</meta-value></custom-meta><custom-meta><meta-name>metadata-grant</meta-name><meta-value>OpenAccess</meta-value></custom-meta><custom-meta><meta-name>abstract-grant</meta-name><meta-value>OpenAccess</meta-value></custom-meta><custom-meta><meta-name>bodypdf-grant</meta-name><meta-value>OpenAccess</meta-value></custom-meta><custom-meta><meta-name>bodyhtml-grant</meta-name><meta-value>OpenAccess</meta-value></custom-meta><custom-meta><meta-name>bibliography-grant</meta-name><meta-value>OpenAccess</meta-value></custom-meta><custom-meta><meta-name>esm-grant</meta-name><meta-value>OpenAccess</meta-value></custom-meta><custom-meta><meta-name>online-first</meta-name><meta-value>false</meta-value></custom-meta><custom-meta><meta-name>pdf-file-reference</meta-name><meta-value>BodyRef/PDF/12879_2019_Article_4270.pdf</meta-value></custom-meta><custom-meta><meta-name>pdf-type</meta-name><meta-value>Typeset</meta-value></custom-meta><custom-meta><meta-name>target-type</meta-name><meta-value>OnlinePDF</meta-value></custom-meta><custom-meta><meta-name>issue-type</meta-name><meta-value>Regular</meta-value></custom-meta><custom-meta><meta-name>article-type</meta-name><meta-value>OriginalPaper</meta-value></custom-meta><custom-meta><meta-name>journal-subject-primary</meta-name><meta-value>Medicine &amp; Public Health</meta-value></custom-meta><custom-meta><meta-name>journal-subject-secondary</meta-name><meta-value>Infectious Diseases</meta-value></custom-meta><custom-meta><meta-name>journal-subject-secondary</meta-name><meta-value>Parasitology</meta-value></custom-meta><custom-meta><meta-name>journal-subject-secondary</meta-name><meta-value>Medical Microbiology</meta-value></custom-meta><custom-meta><meta-name>journal-subject-secondary</meta-name><meta-value>Tropical Medicine</meta-value></custom-meta><custom-meta><meta-name>journal-subject-secondary</meta-name><meta-value>Internal Medicine</meta-value></custom-meta><custom-meta><meta-name>journal-subject-collection</meta-name><meta-value>Medicine</meta-value></custom-meta><custom-meta><meta-name>open-access</meta-name><meta-value>true</meta-value></custom-meta></custom-meta-group></article-meta><notes notes-type="ESMHint"><title>Electronic supplementary material</title><p>The online version of this article (<ext-link xlink:href="https://doi.org/10.1186/s12879-019-4270-2" ext-link-type="doi">https://doi.org/10.1186/s12879-019-4270-2</ext-link>) contains supplementary material, which is available to authorized users.</p></notes></front><body><sec id="Sec1"><title>Background</title><p id="Par19">The hepatitis C virus (HCV) infection causes acute and chronic liver disease and may lead to cirrhosis, liver failure or hepatocellular carcinoma [<xref ref-type="bibr" rid="CR1">1</xref>]. Globally, it is estimated that there are approximately 100 million persons with serological evidence of active or non-active HCV infection, and that HCV causes about 700,000 deaths each year [<xref ref-type="bibr" rid="CR2">2</xref>]. Most cases of acute infection are asymptomatic and remain undiagnosed [<xref ref-type="bibr" rid="CR3">3</xref>]. Currently highly effective pharmacotherapeutic (direct-acting antiviral) treatment options for HCV are now available [<xref ref-type="bibr" rid="CR4">4</xref>]. Spontaneous clearance of HCV can occur within 12 months of infection in 15–45% of infected individuals, in the absence of treatment [<xref ref-type="bibr" rid="CR5">5</xref>]. HCV infection does not result in long-term immunity and reinfection after effective treatment or clearance has been reported [<xref ref-type="bibr" rid="CR6">6</xref>]. In epidemiological scenarios with high prevalence of HCV, multiple exposures may result in infections with HCV of more than one distinct genotype in the same person [<xref ref-type="bibr" rid="CR7">7</xref>].</p><p id="Par20">Illicit drug use – especially by injection and sharing non-sterile or shared injection equipment – is a main risk factor for transmission of HCV [<xref ref-type="bibr" rid="CR8">8</xref>]. Many people who used illicit drugs (PWUIDs) infected with HCV are asymptomatic and/or unaware of their infection, and the continuation of risk activities that contribute to further transmission and an increase in the incidence of HCV [<xref ref-type="bibr" rid="CR9">9</xref>]. Estimates indicate that there are about 16 million individuals who inject drugs worldwide, and unsafe use or sharing of drug paraphernalia (mainly syringes/needles used for drug injecting) is the main agent of virus transmission among users [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR11">11</xref>]. As many as 10 million people who inject drugs may be HCV-infected worldwide, reflecting the strong association of these risk activities with the easy spread of the virus [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR12">12</xref>].</p><p id="Par21">Brazil is one of the emerging economies where the use of mostly stimulant drugs, such as cocaine – used intranasally (powder) or smoked (crack-cocaine and its related forms - merla or oxi) – has increased significantly in the last two decades [<xref ref-type="bibr" rid="CR13">13</xref>–<xref ref-type="bibr" rid="CR15">15</xref>]. Although uncommon, the use of injectable cocaine has been documented also [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR17">17</xref>]. There are several reasons for the high rate of cocaine-products used in Brazil: geographic proximity and un-secured borders with the world’s largest cocaine producers (Peru, Colombia and Bolivia), a young population combined with increases in wealth in the last decade, and the extensive availability combined with the cheap price of cocaine in Brazil (one crack ‘stone’ selling for three Reais, equivalent to US$ 1) [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR18">18</xref>].</p><p id="Par22">Elevated rates of HCV infection have been reported in epidemiological studies with PWUIDs in different Brazilian regions (2 to 29%) [<xref ref-type="bibr" rid="CR19">19</xref>–<xref ref-type="bibr" rid="CR23">23</xref>]. In the Amazon region (Northern Brazil), studies with PWUIDs have indicated a higher prevalence of HCV infection (28 to 37%), highlighting the elevated potential for the acquisition and transmission of HCV in this risk population [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR25">25</xref>]. HCV genotype 1 is predominant among HCV-infected PWUIDs. Several risk factors for HCV infections have been reported: age (≥ 35 years), tattoos, domestic re-use of needles or syringes for medical procedures, injecting drug use, sharing of drug paraphernalia, daily and lengthy drug use histories (&gt; 3 years). However, all studies done with PWUIDs were conducted with small samples and with limited geographic coverage [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR25">25</xref>].</p><p id="Par23">The vast Amazon region in Northern Brazil is a relatively isolated and socio-ecologically diverse environment, with only limited infrastructure and public services. In the Amazon region, studies have already identified the high use of illicit drugs among adolescents and the high prevalence of HBV and HCV infections among PWUIDs [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR27">27</xref>]. In this context, this study assessed a sample of 1666 PWUIDs in the Amazon region (Northern Brazil), collecting relevant epidemiological information on HCV infection and related risk factors and outcomes towards improved understanding of HCV transmission pathways and intervention needs in this particular risk population and socio-geographic context.</p></sec><sec id="Sec2" sec-type="methods"><title>Methods</title><sec id="Sec3"><title>Study sample and setting</title><p id="Par24">This cross-sectional study relied on biological and self-reported socio-behavioral data from a convenience sample of PWUIDs from the municipalities of the state of Amapá and Pará, in the Amazon region (Northern Brazil) (Fig. <xref rid="Fig1" ref-type="fig">1</xref>). Sample recruitment occurred by way of snowball technique<sup>16</sup>. In neighborhoods of the study sites known to be areas of intensive drug consumption, community leaders and other potential recruitment facilitators were identified and invited to assist with participant recruitment for the study. These study facilitators disseminated general information about the study and its objectives in their respective communities, and identified and invited PWUIDs and their relatives and friends as potential study participants. Study eligibility criteria were: (1) use of illicit drugs in the last three months; (2) 18 years of age or older, (3) not under the effect of psychotropic drugs during the meeting with some members of the study team, (4) did not present a risk of death to researchers in the municipality, and (5) willingness to comply with the study protocol, i.e. to provide a biological sample, to complete the epidemiological assessment, and to provide informed consent for study participation.<fig id="Fig1"><label>Fig. 1</label><caption xml:lang="en"><p>Geographical location of municipalities in the Amazon region that people who used illicit drugs (PWUIDs) were accessed. The Brazilian states of Amapá and Pará are represented by the abbreviations AP and PA, respectively. The numbers from 1 to 38 indicate the municipalities where blood samples were collected and information was provided by the PWUIDs (more details on Additional file <xref ref-type="supplementary-material" rid="MOESM1">1</xref>: Figure S1)</p></caption><p><graphic specific-use="HTML" mime-subtype="PNG" xlink:href="MediaObjects/12879_2019_4270_Fig1_HTML.png" id="MO1"/></p></fig></p><p id="Par25">In each municipality, meetings between researchers and facilitators were held in order to establish the approximate number of PWUIDs to be recruited in each neighborhood, and the local recruitment and assessment procedures to perform the data collection. Potential study candidates were screened for study eligibility (based on the study’s inclusion criteria) during specific field research times in each of the research settings; this procedure was repeated on several occasions. If eligible and consented for the study, participants underwent the study assessment procedures in a private, confidential setting. Several spaces were used to hold meetings with PWUIDs, such as: private rooms in commercial establishments, rooms part of the Universidade Federal do Pará (UFPA) and Universidade Federal do Amapá (UNIFAP), public health facilities, private rooms within schools, churches, and community centers. Members of the research team conducted the interview-based assessments and blood collection of the PWUIDs. All sample and data collections, as well as the formal consents for study participation, were provided on the specific day for each neighborhood of the different municipalities. No PWUIDs received financial incentive to participate in this study. All samples and data were collected between March 2013 and January 2018.</p></sec><sec id="Sec4"><title>Data collection</title><p id="Par26">All study participants completed an interviewer-administered questionnaire consisting of question items on socio-demographic, drug use and select clinical/health and behavior outcome variables used in previous studies with similar target populations. The questionnaire contained question items in regards to the following variables: sex, age, colour/race, ethnic origin, marital status, education, amounts and sources of income (last 12 months), blood transfusion and surgical history, tattoos, history and frequency of illicit and other drug use (last 12 months), injection drug use (last 24 months), sharing of drug use equipment (last 12 months), presence of oral or nasal mucosal sores (last 12 months), sexual risk practices (last 12 months), presence of genital ulcers (last 12 months), police arrest/detention (last 12 months), involvement in illicit drug trafficking (last 12 months), and sex work involvement (last 12 months) [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR24">24</xref>]. In this study, unprotected sexual intercourse and multiple sexual partners were considered sexual risk practices.</p></sec><sec id="Sec5"><title>Laboratory tests</title><p id="Par27">Venous blood samples were taken from participants and tested for HCV infection. Specifically, a small blood sample (5 ml) was collected in sterile tubes, allowed to clot, and centrifuged at room temperature. The resulting plasma samples were stored at a temperature below -10 °C. At the end of the collection period at each study site, the samples were transported to UFPA and UNIFAP virological testing laboratories located in Belém, Bragança, Breves and Macapá for laboratory testing. The samples collected were tested for the presence of anti-HCV antibodies and ribonucleic Acid – HCV (HCV-RNA). Anti-HCV antibody was detected using enzyme immunoassay (EIA – Murex anti-HCV 4.0, DiaSorin). The samples were also submitted for the isolation of RNA (QIAmp Viral RNA Mini extraction kit, Qiagen) and transcription of RNA to complementary DNA (cDNA) (High-Capacity cDNA Reverse Transcription kit, Applied Biosystems). These two experiments were performed employing commercial kits according to the manufacturers’ instructions. The 5′ untranslated region (UTR) fragment of HCV was detected by real-time polymerase chain reaction (PCR) [<xref ref-type="bibr" rid="CR17">17</xref>]. When samples were found to be reactive for anti-HCV but negative for HCV-RNA, further confirmation was done using Immuno Blot Assay (RIBA, Chiron). PWUIDs were categorized as actively infected with HCV if they had a positive HCV-RNA and a positive antibody-HCV test. PWUIDs with non-active (past) HCV infection – or spontaneous clearance - were identified when they had a positive antibody-HCV test and a negative HCV-RNA test. The samples presenting HCV-RNA had their genotypes identified by real-time PCR [<xref ref-type="bibr" rid="CR17">17</xref>].</p></sec><sec id="Sec6"><title>Data processing and statistical analysis</title><p id="Par28">All study data collected - including epidemiological indicator data from the participants’ questionnaires - were entered into an Excel database and converted to SPSS. The proportion of participants who had active HCV and non-active (past) HCV infection was assessed. Confidence intervals were computed to estimate the prevalence of HCV infection rates. A descriptive analysis was conducted to investigate the bivariate relationships between HCV status and epidemiological (i.e., socio-demographic, drug use and other health-related) covariates drawn from the epidemiological questionnaire data. All the potential factors with probabilities of <italic>p</italic> ≤ 0.2 were examined and included in the final models of HCV infection (i.e. active + non-active infections) and HCV spontaneous clearance (HSC) status, using backward stepwise multiple logistic regression. Multiple logistic regressions were then run to determine the association of each factor with HCV infection and HSC status. Various possible types of interactions were evaluated in order to determine how they might improve the final models [<xref ref-type="bibr" rid="CR28">28</xref>]. The fit of the final model was assessed using the Hosmer-Lemeshow goodness-of-fit test. All statistical analyses were performed using SPSS 20.0 for Windows, with a level of significance of 0.05.</p></sec></sec><sec id="Sec7" sec-type="results"><title>Results</title><sec id="Sec8"><title>Characteristics of PWUIDs</title><p id="Par29">Of the total sample of 1666 participants recruited into the study, 539 PWUIDs were from nine municipalities of the state of Amapá (32.4%) and 1127 PWUIDs were from twenty-nine municipalities of the state of Pará (67.6%) (Fig. <xref rid="Fig1" ref-type="fig">1</xref>). The number of PWUIDs accessed in each municipality is available in the supporting information (Additional file <xref ref-type="supplementary-material" rid="MOESM1">1</xref>: Figure S1). Respective majorities of the PWUIDs sample were male, aged between 18 to 29 years, heterosexual, single, Brazilian and born in the Amazon region, non-white and with a low/limited level of education. Most participants reported their initial onset of illicit drug use during adolescence, i.e. below the age of 18 years (64.9%). The average monthly income of PWUIDs was around the Brazilian minimum wage standard (approximately 210 US dollars/month), derived from formal or informal employment sources (Table <xref rid="Tab1" ref-type="table">1</xref>).<table-wrap id="Tab1"><label>Table 1</label><caption xml:lang="en"><p>Socio-demographic and economic characteristics of the sample of people who used illicit drugs related to the status of HCV infection</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2"><p>Characteristics</p></th><th rowspan="2"><p>N</p></th><th colspan="3"><p>HCV infection</p></th></tr><tr><th><p>Active % (n)</p></th><th><p>Non-active % (n)</p></th><th><p>Total % (n)</p></th></tr></thead><tbody><tr><td><p>Total sample</p></td><td><p>1666</p></td><td><p>23.0 (384)</p></td><td><p>11.6 (193)</p></td><td><p>34.6 (577)</p></td></tr><tr><td colspan="5"><p>Sex</p></td></tr><tr><td><p> Male</p></td><td><p>1053</p></td><td><p>23.8 (251)</p></td><td><p>10.5 (111)</p></td><td><p>34.3 (362)</p></td></tr><tr><td><p> Female</p></td><td><p>600</p></td><td><p>22.0 (132)</p></td><td><p>13.7 (82)</p></td><td><p>35.7 (214)</p></td></tr><tr><td><p> Transgendered</p></td><td><p>13</p></td><td><p>7.7 (1)</p></td><td><p>0.0 (0)</p></td><td><p>7.7 (1)</p></td></tr><tr><td colspan="5"><p>Age</p></td></tr><tr><td><p> 18–29 years</p></td><td><p>893</p></td><td><p>21.1 (188)</p></td><td><p>13.1 (117)</p></td><td><p>34.2 (305)</p></td></tr><tr><td><p> 30–39 years</p></td><td><p>575</p></td><td><p>21.0 (121)</p></td><td><p>8.9 (51)</p></td><td><p>29.9 (172)</p></td></tr><tr><td><p> 40 + years</p></td><td><p>198</p></td><td><p>37.9 (75)</p></td><td><p>12.6 (25)</p></td><td><p>50.5 (100)</p></td></tr><tr><td colspan="5"><p>Origin</p></td></tr><tr><td><p> Brazilian – Born in the Amazon region</p></td><td><p>1426</p></td><td><p>21.0 (299)</p></td><td><p>13.1 (187)</p></td><td><p>34.1 (486)</p></td></tr><tr><td><p> Brazilian – Not born in the Amazon region</p></td><td><p>224</p></td><td><p>37.0 (83)</p></td><td><p>2.7 (6)</p></td><td><p>39.7 (89)</p></td></tr><tr><td><p> Non-Brazilian</p></td><td><p>162</p></td><td><p>1.2 (2)</p></td><td><p>0.0 (0)</p></td><td><p>1.2 (2)</p></td></tr><tr><td colspan="5"><p>Colour/race</p></td></tr><tr><td><p> White</p></td><td><p>564</p></td><td><p>27.3 (154)</p></td><td><p>9.2 (52)</p></td><td><p>36.5 (206)</p></td></tr><tr><td><p> Non-white</p></td><td><p>1102</p></td><td><p>20.9 (230)</p></td><td><p>12.8 (141)</p></td><td><p>33.7 (371)</p></td></tr><tr><td colspan="5"><p>Sexual orientation</p></td></tr><tr><td><p> Heterosexual</p></td><td><p>1507</p></td><td><p>23.0 (346)</p></td><td><p>11.8 (178)</p></td><td><p>34.8 (524)</p></td></tr><tr><td><p> Same-sex (including bisexual)</p></td><td><p>159</p></td><td><p>23.9 (38)</p></td><td><p>9.4 (15)</p></td><td><p>33.3 (53)</p></td></tr><tr><td colspan="5"><p>Marital status<sup>†</sup></p></td></tr><tr><td><p> Single, separated or widowed</p></td><td><p>1036</p></td><td><p>23.4 (242)</p></td><td><p>10.9 (113)</p></td><td><p>34.3 (355)</p></td></tr><tr><td><p> Married or co-habitating</p></td><td><p>630</p></td><td><p>22.5 (142)</p></td><td><p>12.7 (80)</p></td><td><p>35.2 (222)</p></td></tr><tr><td colspan="5"><p>Education</p></td></tr><tr><td><p> No formal education/some elementary school</p></td><td><p>1009</p></td><td><p>23.0 (232)</p></td><td><p>10.8 (109)</p></td><td><p>33.8 (341)</p></td></tr><tr><td><p> Completed elementary school or higher</p></td><td><p>657</p></td><td><p>23.1 (152)</p></td><td><p>12.8 (84)</p></td><td><p>35.9 (236)</p></td></tr><tr><td colspan="5"><p>Monthly income<sup>†</sup></p></td></tr><tr><td><p> Less than Brazilian minimum wage</p></td><td><p>1118</p></td><td><p>21.5 (241)</p></td><td><p>11.9 (133)</p></td><td><p>33.4 (374)</p></td></tr><tr><td><p> More than Brazilian minimum wage</p></td><td><p>548</p></td><td><p>26.1 (143)</p></td><td><p>10.9 (60)</p></td><td><p>37.0 (203)</p></td></tr><tr><td colspan="5"><p>Income source<sup>†</sup></p></td></tr><tr><td><p> Regular or irregular job</p></td><td><p>1039</p></td><td><p>21.4 (222)</p></td><td><p>9.7 (101)</p></td><td><p>31.1 (323)</p></td></tr><tr><td><p> Social benefits/pension</p></td><td><p>221</p></td><td><p>14.0 (31)</p></td><td><p>17.2 (38)</p></td><td><p>31.2 (69)</p></td></tr><tr><td><p> Criminal activity</p></td><td><p>406</p></td><td><p>32.3 (131)</p></td><td><p>13.3 (54)</p></td><td><p>45.6 (185)</p></td></tr></tbody></table><table-wrap-foot><p><sup>†</sup>Last 12 months</p></table-wrap-foot></table-wrap></p><p id="Par30">All PWUIDs reported frequent use of non-injected drugs in the last 12 months. A sub-group of PWUIDs reported injecting drug use (cocaine) at least once (last 24 months) (14.9%). Most PWUIDs had used illicit drugs for a period of between 5 to 15 years (60.3%), with an average period of 7.5 years. Crack-cocaine or related products (oxi) was the main drug used by most participants (50.2%) (Table <xref rid="Tab2" ref-type="table">2</xref>). Most PWUIDs reported using more than one illicit drug during their lifetime (92.2%), commonly involving marijuana as the initial illicit drug used. The sharing of drug use equipment was common among PWUIDs (<italic>n</italic> = 988, 59.3%) (Table <xref rid="Tab2" ref-type="table">2</xref>), specifically inhalation-pipe sharing was reported by many users of non-injecting drugs (<italic>n</italic> = 795, 47.7%), and syringe and needle sharing among injecting drug users (<italic>n</italic> = 193, 11.6%). Some crack-cocaine users reported sores in their oral or nasal mucosa (34.5%). Participation in the distribution or sale of illicit drugs (17.0%) and a history of police or in prison detention (23.4%) was reported by some PWUIDs (Table <xref rid="Tab2" ref-type="table">2</xref>). Many users reported risky sexual practice or compromised sexual health, including multiple sexual partners and sex work involvement (34.8%), and genital ulcers (46.9%).<table-wrap id="Tab2"><label>Table 2</label><caption xml:lang="en"><p>Sample characteristics related to illicit drug use, illicit activities, sex and risks associated with the status of HCV infection</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2"><p>Characteristics</p></th><th rowspan="2"><p>N</p></th><th colspan="3"><p>HCV infection</p></th></tr><tr><th><p>Active % (n)</p></th><th><p>Non-active % (n)</p></th><th><p>Total % (n)</p></th></tr></thead><tbody><tr><td><p>Total sample</p></td><td><p>1666</p></td><td><p>23.05 (384)</p></td><td><p>11.58 (193)</p></td><td><p>34.63 (577)</p></td></tr><tr><td colspan="5"><p>Main illicit drug used<sup>a</sup></p></td></tr><tr><td><p> Marijuana</p></td><td><p>137</p></td><td><p>9.5 (13)</p></td><td><p>4.4 (6)</p></td><td><p>13.9 (19)</p></td></tr><tr><td><p> Crack/oxi</p></td><td><p>837</p></td><td><p>25.6 (214)</p></td><td><p>11.7 (98)</p></td><td><p>37.3 (312)</p></td></tr><tr><td><p> Cocaine</p></td><td><p>692</p></td><td><p>22.7 (157)</p></td><td><p>12.9 (89)</p></td><td><p>35.6 (246)</p></td></tr><tr><td><p>Daily use of illicit drugs<sup>a</sup></p></td><td><p>1153</p></td><td><p>29.0 (335)</p></td><td><p>13.8 (159)</p></td><td><p>42.8 (494)</p></td></tr><tr><td><p>Over 12 years using illicit drugs</p></td><td><p>549</p></td><td><p>56.4 (310)</p></td><td><p>27.0 (148)</p></td><td><p>83.4 (458)</p></td></tr><tr><td><p>Injecting drug use<sup>b</sup></p></td><td><p>248</p></td><td><p>37.5 (93)</p></td><td><p>17.3 (43)</p></td><td><p>54.8 (136)</p></td></tr><tr><td><p>Sharing of drug use equipment<sup>a</sup></p></td><td><p>988</p></td><td><p>31.5 (311)</p></td><td><p>16.1 (159)</p></td><td><p>47.6 (470)</p></td></tr><tr><td><p>Involvement in illicit drug trafficking<sup>a</sup></p></td><td><p>283</p></td><td><p>47.0 (133)</p></td><td><p>18.4 (52)</p></td><td><p>65.4 (185)</p></td></tr><tr><td><p>Detention (by police or in prison) <sup>a</sup></p></td><td><p>373</p></td><td><p>22.8 (85)</p></td><td><p>14.7 (55)</p></td><td><p>37.5 (140)</p></td></tr><tr><td><p>Unprotected sexual intercourse<sup>a</sup></p></td><td><p>1387</p></td><td><p>25.0 (347)</p></td><td><p>10.7 (149)</p></td><td><p>35.7 (496)</p></td></tr><tr><td><p>More than 12 sexual partners<sup>a</sup></p></td><td><p>828</p></td><td><p>26.0 (215)</p></td><td><p>11.6 (96)</p></td><td><p>37.6 (311)</p></td></tr><tr><td><p>Sex work involvement<sup>a</sup></p></td><td><p>663</p></td><td><p>21.3 (141)</p></td><td><p>11.9 (79)</p></td><td><p>33.2 (220)</p></td></tr><tr><td><p>Blood transfusion history</p></td><td><p>283</p></td><td><p>31.1 (88)</p></td><td><p>6.7 (19)</p></td><td><p>37.8 (107)</p></td></tr><tr><td><p>Tattoos</p></td><td><p>1082</p></td><td><p>29.4 (318)</p></td><td><p>11.5 (124)</p></td><td><p>40.9 (442)</p></td></tr></tbody></table><table-wrap-foot><p><sup>a</sup>Last 12 months. <sup>b</sup>Last 24 months</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec9"><title>HCV infection status and distribution of genotypes</title><p id="Par31">In total, 577 PWUIDs (36.6%) had anti-HCV antibodies by EIA. Among these, 384 PWUIDs also featured HCV-cDNA (23.0%), indicating active HCV infection. Conversely, 193 PWUIDs had anti-HCV antibodies by EIA and immune-blot, with absence of HCV-cDNA by real-time PCR (11.6%), indicating non-active HCV infection, and presented with presumed spontaneous clearance of HCV (Tables <xref rid="Tab1" ref-type="table">1</xref>, <xref rid="Tab2" ref-type="table">2</xref> and <xref rid="Tab3" ref-type="table">3</xref>). In PWUIDs with HCV-cDNA, genotypes 1 (80.2%) and 3 (18.8%) were identified, including four co-infections with these HCV genotypes (1.0%) (Table <xref rid="Tab3" ref-type="table">3</xref>).<table-wrap id="Tab3"><label>Table 3</label><caption xml:lang="en"><p>Prevalence of infection and distribution of HCV genotypes among people who used illicit drugs</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2"><p>Marker</p></th><th colspan="2"><p>Prevalence</p></th><th rowspan="2"><p>95% CI</p></th></tr><tr><th><p>Positive/Total</p></th><th><p>%</p></th></tr></thead><tbody><tr><td colspan="4"><p>HCV infection</p></td></tr><tr><td><p> All (EIA+)</p></td><td><p>577/1666</p></td><td><p>34.6</p></td><td><p>28.3–41.1</p></td></tr><tr><td><p> Active (EIA+ and PCR+)</p></td><td><p>384/1666</p></td><td><p>23.0</p></td><td><p>17.9–28.9</p></td></tr><tr><td><p> Non-active (EIA+ Immuno Blot+ and PCR -)</p></td><td><p>193/1666</p></td><td><p>11.6</p></td><td><p>5.5–18.4</p></td></tr><tr><td colspan="4"><p>Genotypes</p></td></tr><tr><td><p> Genotype 1</p></td><td><p>308/384</p></td><td><p>80.2</p></td><td><p>75.7–85.2</p></td></tr><tr><td><p> Genotype 3</p></td><td><p>72/384</p></td><td><p>18.8</p></td><td><p>12.7–25.0</p></td></tr><tr><td><p> Genotype 1 + Genotype 3</p></td><td><p>4/384</p></td><td><p>1.0</p></td><td><p>0.0–4.6</p></td></tr></tbody></table></table-wrap></p></sec><sec id="Sec10"><title>Characteristics associated with HCV infection</title><p id="Par32">The univariate analysis identified the following socio-behavioral characteristics associated with all HCV infection (i.e. active + non-active infections): age ≥ 30 years, use of crack/oxi + cocaine, daily drug use, &gt; 12 years drug use history, injection drug use, sharing of drug use equipment, involvement in illicit drug trafficking, unsafe sex practices, &gt; 12 sexual partners, and a history of tattoos (Table <xref rid="Tab4" ref-type="table">4</xref>). The multivariate analysis identified an association of the same ten characteristics with all HCV infection. The Hosmer-Lemeshow test indicated that the final model (<sub>HL</sub>χ<sup>2</sup> = 11.23; <italic>p</italic> = 0.25) had an overall good fits. The characteristic most strongly associated with all HCV infection was an illicit drug use history of &gt; 12 years (OR = 27.55). Moreover, two characteristics were associated with non-active HCV infection, or HSC, by way of univariate and multivariate analysis: Brazilian origin (born in the Amazon region) and non-white ethnicity (Table <xref rid="Tab5" ref-type="table">5</xref>). The Hosmer-Lemeshow test indicated that the final model (<sub>HL</sub>χ<sup>2</sup> = 0.32; <italic>p</italic> = 0.59) had a good fit. Brazilian origin (born in the Amazon region) was the main characteristic associated with HSC (OR = 8.84).<table-wrap id="Tab4"><label>Table 4</label><caption xml:lang="en"><p>Bivariate and multivariate analysis of risk factors for HCV infection</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2"><p>Risk factors</p></th><th colspan="2"><p>All HCV infection</p></th></tr><tr><th><p>Bivariate OR (95% CI)</p></th><th><p>Multivariate aOR (95% CI)</p></th></tr></thead><tbody><tr><td colspan="3"><p>Age</p></td></tr><tr><td><p> Up to 29 years</p></td><td><p>1.00</p></td><td><p>1.00</p></td></tr><tr><td><p>  ≥ 30 years</p></td><td><p>1.29 (1.02–1.64)</p></td><td><p>1.10 (1.01–1.75)</p></td></tr><tr><td colspan="3"><p>Main illicit drugs used<sup>a</sup></p></td></tr><tr><td><p> Marijuana</p></td><td><p>1.00</p></td><td><p>1.00</p></td></tr><tr><td><p> Crack/oxi + Cocaine</p></td><td><p>3.58 (2.15–5.87)</p></td><td><p>3.24 (2.03–5.38)</p></td></tr><tr><td colspan="3"><p>Frequency of use of illicit drugs<sup>a</sup></p></td></tr><tr><td><p> Non-daily</p></td><td><p>1.00</p></td><td><p>1.00</p></td></tr><tr><td><p> Daily</p></td><td><p>3.89 (2.96–5.06)</p></td><td><p>4.01 (2.85–5.62)</p></td></tr><tr><td colspan="3"><p>Over 12 years using illicit drugs</p></td></tr><tr><td><p> No</p></td><td><p>1.00</p></td><td><p>1.00</p></td></tr><tr><td><p> Yes</p></td><td><p>29.52 (13.47–52.31)</p></td><td><p>27.55 (13.78–50.23)</p></td></tr><tr><td colspan="3"><p>Injection drug use<sup>b</sup></p></td></tr><tr><td><p> No</p></td><td><p>1.00</p></td><td><p>1.00</p></td></tr><tr><td><p> Yes</p></td><td><p>2.71 (2.03–3.57)</p></td><td><p>3.04 (2.35–4.02)</p></td></tr><tr><td colspan="3"><p>Sharing of drug use equipment<sup>a</sup></p></td></tr><tr><td><p> No</p></td><td><p>1.00</p></td><td><p>1.00</p></td></tr><tr><td><p> Yes</p></td><td><p>4.64 (3.80–6.36)</p></td><td><p>4.18 (3.54–6.07)</p></td></tr><tr><td colspan="3"><p>Involvement in illicit drug trafficking<sup>a</sup></p></td></tr><tr><td><p> No</p></td><td><p>1.00</p></td><td><p>1.00</p></td></tr><tr><td><p> Yes</p></td><td><p>4.77 (3.61–7.16)</p></td><td><p>4.26 (3.35–7.49)</p></td></tr><tr><td colspan="3"><p>Unprotected sexual intercourse<sup>a</sup></p></td></tr><tr><td><p> No</p></td><td><p>1.00</p></td><td><p>1.00</p></td></tr><tr><td><p> Yes</p></td><td><p>1.37 (1.02–1.81)</p></td><td><p>1.22 (1.01–1.69)</p></td></tr><tr><td colspan="3"><p>More than 12 sexual partners<sup>a</sup></p></td></tr><tr><td><p>No</p></td><td><p>1.00</p></td><td><p>1.00</p></td></tr><tr><td><p>Yes</p></td><td><p>1.28 (1.05–1.59)</p></td><td><p>1.19 (1.02–1.75)</p></td></tr><tr><td colspan="3"><p>Tattoos</p></td></tr><tr><td><p> No</p></td><td><p>1.00</p></td><td><p>1.00</p></td></tr><tr><td><p> Yes</p></td><td><p>4.14 (3.11–5.32)</p></td><td><p>3.96 (2.84–4.95)</p></td></tr></tbody></table><table-wrap-foot><p><sup>a</sup>Last 12 months. <sup>b</sup>Last 24 months. Factors not associated with HCV infection can be accessed in Additional file <xref ref-type="supplementary-material" rid="MOESM1">1</xref>: Table S1. OR: Odds Ratio. aOR: adjusted Odds Ratio. 95% CI: 95% Confidence interval</p></table-wrap-foot></table-wrap><table-wrap id="Tab5"><label>Table 5</label><caption xml:lang="en"><p>Bivariate and multivariate analysis of factors associated with HCV spontaneous clearance</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2"><p>Factors</p></th><th colspan="2"><p>HCV spontaneous clearance</p></th></tr><tr><th><p>Bivariate OR (95% CI)</p></th><th><p>Multivariate aOR (95% CI)</p></th></tr></thead><tbody><tr><td colspan="3"><p>Origin</p></td></tr><tr><td><p> Brazilian + Non-Brazilian – Not born in the Amazon region</p></td><td><p>1.00</p></td><td><p>1.00</p></td></tr><tr><td><p> Brazilian – Born in the Amazon region</p></td><td><p>8.84 (3.75–19.81)</p></td><td><p>7.43 (2.54–18.72)</p></td></tr><tr><td colspan="3"><p>Colour/race</p></td></tr><tr><td><p> White</p></td><td><p>1.00</p></td><td><p>1.00</p></td></tr><tr><td><p> Non-White</p></td><td><p>1.80 (1.22–2.71)</p></td><td><p>2.02 (1.28–3.11)</p></td></tr></tbody></table><table-wrap-foot><p>Factors not associated with HCV spontaneous clearance can be accessed in Additional file <xref ref-type="supplementary-material" rid="MOESM1">1</xref>: Table S1. <italic>OR</italic> Odds Ratio, <italic>aOR</italic> Adjusted Odds Ratio, <italic>95% CI</italic> 95% Confidence interval</p></table-wrap-foot></table-wrap></p></sec></sec><sec id="Sec11" sec-type="discussion"><title>Discussion</title><p id="Par33">This study identified important characteristics of the study population of PWUIDs in the Amazon region of Northern Brazil and, specifically, associations with HCV infection status in this vulnerable group. The sample was predominantly composed of men, non-white, young, poor, unmarried, heterosexual and limited education levels. Moreover, some PWUIDs have indicated involvement with sex work, illicit drug trafficking, and the criminal justice system. This information is consistent with findings from other studies in Brazil [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR30">30</xref>]. Some studies have indicated that socioeconomic marginalization contributes to an increased risk of morbidity and mortality among PWUIDs [<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR31">31</xref>]. The strong association between HCV infection and involvement with drug trafficking may represent an example of socioeconomic marginalization contributing to increase the health risks of the PWUIDs. The role of these in the specific study sample requires further examination, which should be done in the future.</p><p id="Par34">Crack and cocaine (used mainly non-injection) were the main illicit drugs consumed by study participants. However, many users may be considered poly-drug users, including some of them reporting - occasional - injection drug use at some point in life. Daily drug use and sharing of drug use equipment were characteristics common for most of the study participants. These findings corroborate information provided in other epidemiological studies conducted with PWUIDs in Brazil, including from the Amazon region [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR19">19</xref>–<xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR24">24</xref>–<xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR30">30</xref>].</p><p id="Par35">The estimated prevalence of HCV infection in the Amazon region’s general population ranges from 1 to 3%, based on the diagnostic methods used, with higher rates being recorded in different sub- or risk groups (e.g., older ages, indigenous) [<xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR32">32</xref>–<xref ref-type="bibr" rid="CR34">34</xref>]. HCV prevalence estimates from previous studies have been multifold higher among PWUIDs, ranging from 28 to 37%, compared to general populations [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR23">23</xref>–<xref ref-type="bibr" rid="CR25">25</xref>]. The present study confirmed the high prevalence of HCV infection (36.6%) among PWUIDs in the Amazon region, reinforcing the need for effective control and prevention measures. The predominance of genotype 1 was observed among PWUIDs, but frequency of the genotype 3 was elevated relative to other risk population in the Amazon region, such as patients with chronic hematologic diseases (recipients of multiple blood transfusions) and patients undergoing hemodialysis [<xref ref-type="bibr" rid="CR35">35</xref>, <xref ref-type="bibr" rid="CR36">36</xref>]. Most HCV infections in the Amazon region consist of genotype 1, whereas genotype 3 is found mostly among PWUIDs [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR35">35</xref>–<xref ref-type="bibr" rid="CR37">37</xref>]. The rapid spread of genotypes 1 and 3 (and specifically subtypes 1a and 3a), in different geographic areas over the past decades, has been a consequence of efficient transmission through unsafe blood transfusion products and injecting drug use [<xref ref-type="bibr" rid="CR38">38</xref>–<xref ref-type="bibr" rid="CR40">40</xref>].</p><p id="Par36">This study is a first in describing HCV infection status (i.e. active and non-active) in a multi-site PWUIDs population in the Amazon region in Northern Brazil. Among 577 PWUIDs infected with HCV, 193 (33.4%) presented with HCV spontaneous clearance. The multivariate analysis suggested spontaneous clearance status to be strongly associated with origin (Amazonian-born) and non-white (e.g., Black or Indigenous) of the participants. The contemporary population of Northern Brazil is comprised of a heterogeneous socio-ethnic mixture of indigenous Brazilian natives combined with migratory populations of Caucasians and Blacks of diverse origins [<xref ref-type="bibr" rid="CR41">41</xref>]. Likely, a predominance of indigenous descent, and associated genetic factors, is a variable behind this strong association of socio-ethnic origin with HCV spontaneous clearance. Genetic ancestry analysis markers were not used in this study, but related finding have also been detected in other studies, including native/indigenous people in North America [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR42">42</xref>]. In Canada, a study conducted with PWUIDs found that Indigenous/Aboriginal status was a factor associated with HCV spontaneous clearance [<xref ref-type="bibr" rid="CR42">42</xref>]. The understanding of factors that promote or prevent the generation of protective immunity is potentially crucial for the development especially of improved prevention (e.g., a possible HCV vaccine) and/or treatment tools for HCV infection; further studies are needed from a clinical and virological perspective on these issues.</p><p id="Par37">HCV infection status was associated with several risk factors in this study, most of which have previously been identified by other studies in Brazil [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR19">19</xref>–<xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR43">43</xref>]. The presence of tattoos and older age (&gt; 30 years) are characteristic known to be associated with HCV infection in PWUIDs and Amazonian blood donors [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR32">32</xref>]. Longer histories (&gt; 12 years) of illicit drug use was the characteristic most strongly associated with HCV infection status, implying extended opportunity for and exposure to repeated key risk behaviors facilitating the acquisition of HCV and other pathogens, such as: sharing of drug use equipment, and injection drug use [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR19">19</xref>–<xref ref-type="bibr" rid="CR21">21</xref>]. The active involvement with drug trafficking as a risk factor likely provides quick and easy access to a greater number of different drugs (e.g., injectable cocaine) as well as riskier use methods (e.g., drug injecting), and so provides increased risk pathways to HCV transmission. Moreover, those newly infected with HCV can continue to transmit HCV to other users through the shared use of non-injection equipment (i.e., crack smoking paraphernalia). The possibility of HCV transmission by shared non-injection equipment has been demonstrated by studies in several countries, including studies in the Amazon region [<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR43">43</xref>–<xref ref-type="bibr" rid="CR46">46</xref>]. Recently, the presence of HCV-RNA in paraphernalia for crack-cocaine consumption (pipes and aluminum cans) was detected among samples from the Amazon region [<xref ref-type="bibr" rid="CR46">46</xref>]. Studies have suggested that the risk of HCV transmission by shared non-injection paraphernalia would be modulated by the presence oral wounds and types of paraphernalia (i.e., sharp or heat-intensive materials) used [<xref ref-type="bibr" rid="CR44">44</xref>–<xref ref-type="bibr" rid="CR46">46</xref>].</p><p id="Par38">Sexual transmission of HCV is still controversially discussed, but considered possible [<xref ref-type="bibr" rid="CR47">47</xref>]. Sexual transmission of HCV has been more commonly recorded in men-who-have-sex-with-men featuring high sexual (e.g., HIV) and drug use risks status [<xref ref-type="bibr" rid="CR48">48</xref>]. Other studies have indicated the possibility of sexual transmission of HCV among PWUIDs with sexually transmitted infections (STIs), especially with the presence of oral and/or genital wounds [<xref ref-type="bibr" rid="CR49">49</xref>, <xref ref-type="bibr" rid="CR50">50</xref>]. High levels of syphilis and HCV-HIV co-infection among PWUIDs have been documented previously in the Amazon region [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR51">51</xref>]. These dynamics likely are involved in the associations of unprotected sexual intercourse with HCV infection status in the present study sample. An evaluation of HCV co-infections with other pathogens such as HBV, HIV, HTLV and <italic>T. pallidum</italic> in the present sample – confounded by poor health care resources and infrastructure in the study region – will be carried out separately to further examine this comprehensive epidemiological-virological picture.</p><p id="Par39">The present study has a number of possible limitations. One limiting factor was the age limit criterion (18 years) applied for eligible participants, since many PWUIDs report an onset of illicit drug use at ages &lt; 18 years. Second, the restriction of the study to the municipalities of the Amazon region renders the study sample not necessarily representative of the PWUIDs population in Northern Brazil more generally. In addition, although snowball sampling has been found to be adequate for quasi-representative sampling in hidden populations, could have been used to improve representativeness. As the interview data are self-reported, some information, such as drug use or sex-related risks behaviors, may contain response or recall bias. Screening for HCV infection was based on EIA, recent infections may present a small concentration of anti-HCV antibodies, not yet detected by EIA, and therefore may have been diagnosed as negative. Finally, the cross-sectional design of the study limits its capacity to establish causality.</p></sec><sec id="Sec12" sec-type="conclusions"><title>Conclusions</title><p id="Par40">The present study is the first epidemiological examination of HCV infection (active or non-active) status and related risk factors among a large, multi-site sample of PWUIDs in the Amazon region. High levels of HCV infection – predominantly genotype 1 and associated drug use intensity, sexual risks and social marginalization – as well as spontaneous clearance were identified. The results, despite the context of an underdeveloped health care structure, emphasize the urgent need for improved HCV prevention and care services for marginalized drug users in the Brazilian Amazon region, yet also for improved understanding of HCV transmission risks and especially those factors facilitating spontaneous clearance for HCV in the study’s target population.</p></sec></body><back><ack><title>Acknowledgements</title><p>The authors are grateful for the generous assistance of the facilitators who collaborated with the recruitment of the PWUIDs in the study sites. ABOF acknowledges research support from Universidade Federal do Pará, Brazil. RLR acknowledges research support from Universidade Federal do Amapá, Brazil. BF acknowledges research support from the Hugh Green Chair in Addiction Research, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand, and from the Chair in Addiction, Department of Psychiatry, University of Toronto, Canada.</p></ack><sec sec-type="author-contribution"><title>Authors’ contributions</title><p>All authors contributed to the development of research. Study design: ABOF, JARL. Investigation and methodology: ABOF, FJAS, FQS, NCR, CCSC, JNFP, LCM, YMNC, JFFDM, RLR, GCSO, LMLP, LFAM, JRRP, EK, JARL. Formal analysis: ABOF, NCR, LCM, RLR, GCSO, LFAM, JRRP, EK, BF. Writing – original draft: ABOF. Writing – review &amp; editing: CCSC, NCR, FJAS, FQS, JNFP, LCM, YMNC, JFFDM, RLR, GCSO, LMLP, LFAM, JRRP, EK, JARL, BF. Project administration: ABOF, LCM, RLR, GCSO, LMLP, JARL. Funding acquisition: ABOF, JRRP, JARL, BF. All authors read and approved the final manuscript.</p></sec><sec><title>Funding</title><p>Ministério da Saúde/Secretaria de Vigilância em Saúde (MS/SVS) and Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPQ) provided financial resources for the purchase of reagents and commercial kits used in this study. The authors FJAS, FQS, NCR, YMNC, and JFFDM received CNPQ fellowships to develop the study. The authors CCSC and JNFP received Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) fellowships to develop the study.</p></sec><sec sec-type="data-availability"><title>Availability of data and materials</title><p>The datasets analyzed during the current study are not publicly available due to the progress of analyzes of possible infections and co-infections with other pathogens, but are available from the corresponding author on reasonable request.</p></sec><sec sec-type="ethics-statement"><sec id="FPar1"><title>Ethics approval and consent to participate</title><p id="Par41">All participants were included after providing informed and written consent. They received laboratory test results, and participants infected with HCV were directed to treatment in the public health network. All procedures have been performed in accordance with the relevant guidelines and regulations. This study was approved by the Committee for Ethics in Research of the Núcleo de Medicina Tropical of the UFPA in Belém, Brazil (CAAE: 37536314.4.0000.5172).</p></sec><sec id="FPar2"><title>Consent for publication</title><p id="Par42">Not applicable.</p></sec><sec id="FPar3" sec-type="COI-statement"><title>Competing interests</title><p id="Par43">The authors declare that they have no competing interests.</p></sec></sec><ref-list id="Bib1"><title>References</title><ref-list><ref id="CR1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Te</surname><given-names>HS</given-names></name><name><surname>Jensen</surname><given-names>DM</given-names></name></person-group><article-title xml:lang="en">Epidemiology of hepatitis B and C viruses: a global overview</article-title><source>Clin Liver Dis</source><year>2010</year><volume>14</volume><fpage>1</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1016/j.cld.2009.11.009</pub-id><pub-id pub-id-type="pmid">20123436</pub-id></mixed-citation></ref><ref id="CR2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lanini</surname><given-names>S</given-names></name><name><surname>Easterbrook</surname><given-names>PJ</given-names></name><name><surname>Zumla</surname><given-names>A</given-names></name><name><surname>Ippolito</surname><given-names>G</given-names></name></person-group><article-title xml:lang="en">Hepatitis C: global epidemiology and strategies for control</article-title><source>Clin Microbiol Infect</source><year>2016</year><volume>22</volume><fpage>833</fpage><lpage>838</lpage><pub-id pub-id-type="coi">1:STN:280:DC%2BC2szgsFSqtA%3D%3D</pub-id><pub-id pub-id-type="doi">10.1016/j.cmi.2016.07.035</pub-id><pub-id pub-id-type="pmid">27521803</pub-id></mixed-citation></ref><ref id="CR3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Westbrook</surname><given-names>RH</given-names></name><name><surname>Dusheiko</surname><given-names>G</given-names></name></person-group><article-title xml:lang="en">Natural history of hepatitis C</article-title><source>J Hepatol</source><year>2014</year><volume>61</volume><fpage>S58</fpage><lpage>S68</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2014.07.012</pub-id><pub-id pub-id-type="pmid">25443346</pub-id></mixed-citation></ref><ref id="CR4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Asselah</surname><given-names>T</given-names></name><name><surname>Boyer</surname><given-names>N</given-names></name><name><surname>Saadoun</surname><given-names>D</given-names></name><etal/></person-group><article-title xml:lang="en">Direct-acting antivirals for the treatment of hepatitis C virus infection: optimizing current IFN-free treatment and future perspectives</article-title><source>Liver Int</source><year>2016</year><volume>36</volume><fpage>47</fpage><lpage>57</lpage><pub-id pub-id-type="doi">10.1111/liv.13027</pub-id><pub-id pub-id-type="pmid">26725897</pub-id></mixed-citation></ref><ref id="CR5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aisyah</surname><given-names>DN</given-names></name><name><surname>Shallcross</surname><given-names>L</given-names></name><name><surname>Hully</surname><given-names>AJ</given-names></name><etal/></person-group><article-title xml:lang="en">Assessing hepatitis C spontaneous clearance and understanding associated factors - a systematic review and meta-analysis</article-title><source>J Viral Hepat</source><year>2018</year><volume>25</volume><fpage>680</fpage><lpage>698</lpage><pub-id pub-id-type="coi">1:STN:280:DC%2BC1MvhvFSqtQ%3D%3D</pub-id><pub-id pub-id-type="doi">10.1111/jvh.12866</pub-id><pub-id pub-id-type="pmid">29345844</pub-id></mixed-citation></ref><ref id="CR6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cunningham</surname><given-names>EB</given-names></name><name><surname>Applegate</surname><given-names>TL</given-names></name><name><surname>Lloyd</surname><given-names>AR</given-names></name><etal/></person-group><article-title xml:lang="en">Mixed HCV infection and reinfection in people who inject drugseimpact on therapy</article-title><source>Nat Rev Gastroenterol Hepatol</source><year>2015</year><volume>12</volume><fpage>218</fpage><lpage>230</lpage><pub-id pub-id-type="coi">1:CAS:528:DC%2BC2MXkvVyiurk%3D</pub-id><pub-id pub-id-type="doi">10.1038/nrgastro.2015.36</pub-id><pub-id pub-id-type="pmid">25782091</pub-id></mixed-citation></ref><ref id="CR7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Layden</surname><given-names>JE</given-names></name><name><surname>Phillips</surname><given-names>RO</given-names></name><name><surname>Owusu-Ofori</surname><given-names>S</given-names></name><etal/></person-group><article-title xml:lang="en">High frequency of active HCV infection among seropositive cases in West Africa and evidence for multiple transmission pathways</article-title><source>Clin Infect Dis</source><year>2015</year><volume>60</volume><fpage>1033</fpage><lpage>1041</lpage><pub-id pub-id-type="doi">10.1093/cid/ciu965</pub-id><pub-id pub-id-type="pmid">25477425</pub-id></mixed-citation></ref><ref id="CR8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aceijas</surname><given-names>C</given-names></name><name><surname>Rhodes</surname><given-names>T</given-names></name></person-group><article-title xml:lang="en">Global estimates of prevalence of HCV infection among injecting drug users</article-title><source>Int J Drug Policy</source><year>2007</year><volume>18</volume><fpage>352</fpage><lpage>358</lpage><pub-id pub-id-type="doi">10.1016/j.drugpo.2007.04.004</pub-id><pub-id pub-id-type="pmid">17854722</pub-id></mixed-citation></ref><ref id="CR9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scheinmann</surname><given-names>R</given-names></name><name><surname>Hagan</surname><given-names>H</given-names></name><name><surname>Lelutiu-Weinberger</surname><given-names>C</given-names></name><etal/></person-group><article-title xml:lang="en">Non-injection drug use and hepatitis C virus: a systematic review</article-title><source>Drug Alcohol Depend</source><year>2007</year><volume>89</volume><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1016/j.drugalcdep.2006.11.014</pub-id><pub-id pub-id-type="pmid">17174481</pub-id></mixed-citation></ref><ref id="CR10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mathers</surname><given-names>BM</given-names></name><name><surname>Degenhardt</surname><given-names>L</given-names></name><name><surname>Phillips</surname><given-names>B</given-names></name><etal/></person-group><article-title xml:lang="en">Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review</article-title><source>Lancet.</source><year>2008</year><volume>372</volume><fpage>1733</fpage><lpage>1745</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(08)61311-2</pub-id><pub-id pub-id-type="pmid">18817968</pub-id></mixed-citation></ref><ref id="CR11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Degenhardt</surname><given-names>L</given-names></name><name><surname>Hall</surname><given-names>W</given-names></name></person-group><article-title xml:lang="en">Extent of illicit drug use and dependence, and their contribution to the global burden of disease</article-title><source>Lancet.</source><year>2012</year><volume>379</volume><fpage>55</fpage><lpage>70</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(11)61138-0</pub-id><pub-id pub-id-type="pmid">22225671</pub-id></mixed-citation></ref><ref id="CR12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nelson</surname><given-names>PK</given-names></name><name><surname>Mathers</surname><given-names>BM</given-names></name><name><surname>Cowie</surname><given-names>B</given-names></name><etal/></person-group><article-title xml:lang="en">Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews</article-title><source>Lancet</source><year>2011</year><volume>13</volume><fpage>571</fpage><lpage>583</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(11)61097-0</pub-id></mixed-citation></ref><ref id="CR13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duailibi</surname><given-names>LB</given-names></name><name><surname>Ribeiro</surname><given-names>M</given-names></name><name><surname>Laranjeira</surname><given-names>R</given-names></name></person-group><article-title xml:lang="en">Profile of cocaine and crack users in Brazil</article-title><source>Cad Saude Publica</source><year>2008</year><volume>24</volume><fpage>545</fpage><lpage>557</lpage><pub-id pub-id-type="doi">10.1590/S0102-311X2008001600007</pub-id></mixed-citation></ref><ref id="CR14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fischer</surname><given-names>B</given-names></name><name><surname>Santos Cruz</surname><given-names>M</given-names></name><name><surname>Bastos</surname><given-names>FI</given-names></name><etal/></person-group><article-title xml:lang="en">Crack across the Americas - a massive problem in continued search of viable answers: exemplary views from the north (Canada) and the south (Brazil)</article-title><source>Int J Drug Policy</source><year>2013</year><volume>24</volume><fpage>631</fpage><lpage>633</lpage><pub-id pub-id-type="doi">10.1016/j.drugpo.2013.09.003</pub-id><pub-id pub-id-type="pmid">24120442</pub-id></mixed-citation></ref><ref id="CR15"><label>15.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><collab>United Nations Office on Drugs and Crime</collab></person-group><source>World Drug Report 2012</source><year>2012</year><pub-id pub-id-type="doi">10.18356/94bbf1f4-en</pub-id><comment>https://www.unodc.org/documents/lpo-brazil/Topics_drugs/WDR/2012/WDR_2012_web_small.pdf. Accessed 3 Aug 2018</comment></mixed-citation></ref><ref id="CR16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oliveira-Filho</surname><given-names>AB</given-names></name><name><surname>Sawada</surname><given-names>L</given-names></name><name><surname>Pinto</surname><given-names>LC</given-names></name><etal/></person-group><article-title xml:lang="en">HCV infection among cocaine users in the state of Pará, Brazilian Amazon</article-title><source>Arch Virol</source><year>2013</year><volume>158</volume><fpage>1555</fpage><lpage>1560</lpage><pub-id pub-id-type="coi">1:CAS:528:DC%2BC3sXhtVCqs77L</pub-id><pub-id pub-id-type="doi">10.1007/s00705-013-1627-5</pub-id><pub-id pub-id-type="pmid">23408127</pub-id></mixed-citation></ref><ref id="CR17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silva</surname><given-names>FQ</given-names></name><name><surname>Santos</surname><given-names>FJA</given-names></name><name><surname>Andrade</surname><given-names>AP</given-names></name><etal/></person-group><article-title xml:lang="en">Hepatitis C virus infection among illicit drug users in an archipelago of the Amazon</article-title><source>Arch Virol</source><year>2018</year><volume>163</volume><fpage>617</fpage><lpage>622</lpage><pub-id pub-id-type="coi">1:CAS:528:DC%2BC2sXhvVKiu7rL</pub-id><pub-id pub-id-type="doi">10.1007/s00705-017-3656-y</pub-id><pub-id pub-id-type="pmid">29164400</pub-id></mixed-citation></ref><ref id="CR18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abdalla</surname><given-names>RR</given-names></name><name><surname>Madruga</surname><given-names>CS</given-names></name><name><surname>Ribeiro</surname><given-names>M</given-names></name><etal/></person-group><article-title xml:lang="en">Prevalence of cocaine use in Brazil: data from the II Brazilian national alcohol and drugs survey (BNADS)</article-title><source>Addict Behav</source><year>2014</year><volume>39</volume><fpage>297</fpage><lpage>301</lpage><pub-id pub-id-type="doi">10.1016/j.addbeh.2013.10.019</pub-id><pub-id pub-id-type="pmid">24455783</pub-id></mixed-citation></ref><ref id="CR19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lopes</surname><given-names>CL</given-names></name><name><surname>Teles</surname><given-names>SA</given-names></name><name><surname>Espírito-Santo</surname><given-names>MP</given-names></name><etal/></person-group><article-title xml:lang="en">Prevalence, risk factors and genotypes of hepatitis C virus infection among drug users, Central-Western Brazil</article-title><source>Rev Saude Publica</source><year>2009</year><volume>43</volume><fpage>43</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1590/S0034-89102009000800008</pub-id><pub-id pub-id-type="pmid">19669064</pub-id></mixed-citation></ref><ref id="CR20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oliveira</surname><given-names>ML</given-names></name><name><surname>Yoshida</surname><given-names>CF</given-names></name><name><surname>Telles</surname><given-names>PR</given-names></name><etal/></person-group><article-title xml:lang="en">Trends in HCV prevalence, risk factors and distribution of viral genotypes in injecting drug users: findings from two cross-sectional studies</article-title><source>Epidemiol Infect</source><year>2009</year><volume>137</volume><fpage>970</fpage><lpage>979</lpage><pub-id pub-id-type="coi">1:STN:280:DC%2BD1MzntlSisA%3D%3D</pub-id><pub-id pub-id-type="doi">10.1017/S0950268808001970</pub-id><pub-id pub-id-type="pmid">19144250</pub-id></mixed-citation></ref><ref id="CR21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nunes</surname><given-names>CL</given-names></name><name><surname>Andrade</surname><given-names>T</given-names></name><name><surname>Galvão-Castro</surname><given-names>B</given-names></name><etal/></person-group><article-title xml:lang="en">Assessing risk behaviors and prevalence of sexually transmitted and blood-borne infections among female crack cocaine users in Salvador-Bahia, Brazil</article-title><source>Braz J Infect Dis</source><year>2007</year><volume>11</volume><fpage>561</fpage><lpage>566</lpage><pub-id pub-id-type="doi">10.1590/S1413-86702007000600007</pub-id><pub-id pub-id-type="pmid">18327467</pub-id></mixed-citation></ref><ref id="CR22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pereira</surname><given-names>LM</given-names></name><name><surname>Martelli</surname><given-names>CM</given-names></name><name><surname>Moreira</surname><given-names>RC</given-names></name><etal/></person-group><article-title xml:lang="en">Prevalence and risk factors of hepatitis C virus infection in Brazil, 2005 through 2009: a cross-sectional study</article-title><source>BMC Infect Dis</source><year>2013</year><volume>13</volume><fpage>60</fpage><pub-id pub-id-type="doi">10.1186/1471-2334-13-60</pub-id><pub-id pub-id-type="pmid">23374914</pub-id><pub-id pub-id-type="pmcid">3574834</pub-id></mixed-citation></ref><ref id="CR23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silva</surname><given-names>MB</given-names></name><name><surname>Andrade</surname><given-names>TM</given-names></name><name><surname>Silva</surname><given-names>LK</given-names></name><etal/></person-group><article-title xml:lang="en">Prevalence and genotypes of hepatitis C virus among injecting drug users from Salvador-BA, Brazil</article-title><source>Mem Inst Oswaldo Cruz</source><year>2010</year><volume>105</volume><fpage>299</fpage><lpage>303</lpage><pub-id pub-id-type="doi">10.1590/S0074-02762010000300009</pub-id><pub-id pub-id-type="pmid">20512243</pub-id></mixed-citation></ref><ref id="CR24"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oliveira-Filho</surname><given-names>AB</given-names></name><name><surname>Sawada</surname><given-names>L</given-names></name><name><surname>Pinto</surname><given-names>LC</given-names></name><etal/></person-group><article-title xml:lang="en">Epidemiological aspects of HCV infection in non-injecting drug users in the Brazilian state of Pará, eastern Amazon</article-title><source>Virol J</source><year>2014</year><volume>11</volume><fpage>38</fpage><pub-id pub-id-type="doi">10.1186/1743-422X-11-38</pub-id><pub-id pub-id-type="pmid">24564954</pub-id><pub-id pub-id-type="pmcid">4077103</pub-id></mixed-citation></ref><ref id="CR25"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pacheco</surname><given-names>SD</given-names></name><name><surname>Silva-Oliveira</surname><given-names>GC</given-names></name><name><surname>Maradei-Pereira</surname><given-names>LM</given-names></name><etal/></person-group><article-title xml:lang="en">Prevalence of HCV infection and associated factors among illicit drug users in Breves, State of Pará, Northern Brazil</article-title><source>Rev Soc Bras Med Trop</source><year>2014</year><volume>47</volume><fpage>367</fpage><lpage>370</lpage><pub-id pub-id-type="doi">10.1590/0037-8682-0153-2013</pub-id><pub-id pub-id-type="pmid">24728470</pub-id></mixed-citation></ref><ref id="CR26"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andrade</surname><given-names>AP</given-names></name><name><surname>Pacheco</surname><given-names>SD</given-names></name><name><surname>Silva</surname><given-names>FQ</given-names></name><etal/></person-group><article-title xml:lang="en">Characterization of hepatitis B virus infection in illicit drug users in the Marajó archipelago, Northern Brazil</article-title><source>Arch Virol</source><year>2017</year><volume>162</volume><fpage>227</fpage><lpage>233</lpage><pub-id pub-id-type="coi">1:CAS:528:DC%2BC28Xhs1Cgur3M</pub-id><pub-id pub-id-type="doi">10.1007/s00705-016-3060-z</pub-id><pub-id pub-id-type="pmid">27718074</pub-id></mixed-citation></ref><ref id="CR27"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Furtado</surname><given-names>IM</given-names></name><name><surname>Araujo</surname><given-names>LG</given-names></name><name><surname>Almeida</surname><given-names>JM</given-names></name><etal/></person-group><article-title xml:lang="en">Use of marijuana and cocaine among students in the municipality of Breves, Marajó archipelago, Brazilian Amazon</article-title><source>J Drug Abuse</source><year>2017</year><volume>3</volume><fpage>1</fpage><pub-id pub-id-type="doi">10.21767/2471-853x.100041</pub-id></mixed-citation></ref><ref id="CR28"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Valois</surname><given-names>RC</given-names></name><name><surname>Maradei-Pereira</surname><given-names>LMC</given-names></name><name><surname>Crescente</surname><given-names>JA</given-names></name><etal/></person-group><article-title xml:lang="en">HCV infection through perforating and cutting material among candidates for blood donation in Belém, Brazilian Amazon</article-title><source>Rev Inst Med Trop Sao Paulo</source><year>2014</year><volume>56</volume><fpage>511</fpage><lpage>515</lpage><pub-id pub-id-type="doi">10.1590/S0036-46652014000600010</pub-id><pub-id pub-id-type="pmid">25351546</pub-id><pub-id pub-id-type="pmcid">4296872</pub-id></mixed-citation></ref><ref id="CR29"><label>29.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Santos</surname><given-names>FJA</given-names></name><name><surname>Silva</surname><given-names>FQ</given-names></name><name><surname>Reis</surname><given-names>ER</given-names></name><etal/></person-group><article-title xml:lang="en">Cocaine and their derivatives: initial report on the features and health indicators of users in municipalities of the Brazilian Amazon</article-title><source>Drug Addiction</source><year>2017</year><comment>http://www.avidscience.com/wp-content/uploads/2017/10/cocaine-and-their-derivatives-initial-report-on-the-features-and-health-indicators-of-users-in-municipalities-of-the-brazilian-amazon.pdf. Accessed 3 Aug 2018</comment></mixed-citation></ref><ref id="CR30"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Santos Cruz</surname><given-names>M</given-names></name><name><surname>Andrade</surname><given-names>T</given-names></name><name><surname>Bastos</surname><given-names>FI</given-names></name><etal/></person-group><article-title xml:lang="en">Key drug use, health and socio-economic characteristics of young crack users in two Brazilian cities</article-title><source>Int J Drug Policy</source><year>2013</year><volume>24</volume><fpage>432</fpage><lpage>438</lpage><pub-id pub-id-type="doi">10.1016/j.drugpo.2013.03.012</pub-id><pub-id pub-id-type="pmid">23632130</pub-id></mixed-citation></ref><ref id="CR31"><label>31.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Butler</surname><given-names>AJ</given-names></name><name><surname>Rehm</surname><given-names>J</given-names></name><name><surname>Fischer</surname><given-names>B</given-names></name></person-group><article-title xml:lang="en">Health outcomes associated with crack-cocaine use: systematic review and meta-analyses</article-title><source>Drug Alcohol Depend</source><year>2017</year><volume>180</volume><fpage>401</fpage><lpage>416</lpage><pub-id pub-id-type="coi">1:CAS:528:DC%2BC2sXhsF2gsrjI</pub-id><pub-id pub-id-type="doi">10.1016/j.drugalcdep.2017.08.036</pub-id><pub-id pub-id-type="pmid">28982092</pub-id></mixed-citation></ref><ref id="CR32"><label>32.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oliveira-Filho</surname><given-names>AB</given-names></name><name><surname>Pimenta</surname><given-names>AS</given-names></name><name><surname>Rojas</surname><given-names>MF</given-names></name><etal/></person-group><article-title xml:lang="en">Prevalence and genotyping of hepatitis C virus in blood donors in the state of Pará, Northern Brazil</article-title><source>Mem Inst Oswaldo Cruz</source><year>2010</year><volume>105</volume><fpage>103</fpage><lpage>106</lpage><pub-id pub-id-type="coi">1:CAS:528:DC%2BC3cXntFyiu7w%3D</pub-id><pub-id pub-id-type="doi">10.1590/S0074-02762010000100016</pub-id><pub-id pub-id-type="pmid">20209338</pub-id></mixed-citation></ref><ref id="CR33"><label>33.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferrari</surname><given-names>JO</given-names></name><name><surname>Ferreira</surname><given-names>MU</given-names></name><name><surname>Tanaka</surname><given-names>A</given-names></name><etal/></person-group><article-title xml:lang="en">The seroprevalence of hepatitis B and C in an Amerindian population in the southwestern Brazilian Amazon</article-title><source>Rev Soc Bras Med Trop</source><year>1999</year><volume>32</volume><fpage>299</fpage><lpage>302</lpage><pub-id pub-id-type="coi">1:STN:280:DyaK1MzgvFKluw%3D%3D</pub-id><pub-id pub-id-type="doi">10.1590/S0037-86821999000300013</pub-id></mixed-citation></ref><ref id="CR34"><label>34.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Paula</surname><given-names>VS</given-names></name><name><surname>Arruda</surname><given-names>ME</given-names></name><name><surname>Vitral</surname><given-names>CL</given-names></name><etal/></person-group><article-title xml:lang="en">Seroprevalence of viral hepatitis in riverine communities from the western region of the Brazilian Amazon Basin</article-title><source>Mem Inst Oswaldo Cruz</source><year>2001</year><volume>96</volume><fpage>1123</fpage><lpage>1128</lpage><pub-id pub-id-type="doi">10.1590/S0074-02762001000800016</pub-id><pub-id pub-id-type="pmid">11784933</pub-id></mixed-citation></ref><ref id="CR35"><label>35.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Freitas</surname><given-names>MJR</given-names></name><name><surname>Fecury</surname><given-names>AA</given-names></name><name><surname>de Almeida</surname><given-names>MK</given-names></name><etal/></person-group><article-title xml:lang="en">Prevalence of hepatitis C virus infection and genotypes in patient with chronic kidney disease undergoing hemodialysis</article-title><source>J Med Virol</source><year>2013</year><volume>85</volume><fpage>1741</fpage><lpage>1745</lpage><pub-id pub-id-type="doi">10.1002/jmv.23654</pub-id><pub-id pub-id-type="pmid">23852735</pub-id></mixed-citation></ref><ref id="CR36"><label>36.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sawada</surname><given-names>L</given-names></name><name><surname>Pinheiro</surname><given-names>AC</given-names></name><name><surname>Locks</surname><given-names>D</given-names></name><etal/></person-group><article-title xml:lang="en">Distribution of hepatitis C virus genotypes among different exposure categories in the State of Pará, Brazilian Amazon</article-title><source>Rev Soc Bras Med Trop</source><year>2011</year><volume>44</volume><fpage>8</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1590/S0037-86822011000100003</pub-id><pub-id pub-id-type="pmid">21340399</pub-id></mixed-citation></ref><ref id="CR37"><label>37.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Araújo</surname><given-names>AR</given-names></name><name><surname>Almeida</surname><given-names>CM</given-names></name><name><surname>Fraporti</surname><given-names>L</given-names></name><etal/></person-group><article-title xml:lang="en">Characterization of hepatitis C virus in chronic hepatitis patients: genotypes in the State of Amazonas, Brazil</article-title><source>Rev Soc Bras Med Trop</source><year>2011</year><volume>44</volume><fpage>638</fpage><lpage>640</lpage><pub-id pub-id-type="doi">10.1590/S0037-86822011000500024</pub-id><pub-id pub-id-type="pmid">22031084</pub-id></mixed-citation></ref><ref id="CR38"><label>38.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prati</surname><given-names>D</given-names></name></person-group><article-title xml:lang="en">Transmission of hepatitis C virus by blood transfusions and other medical procedures: a global review</article-title><source>J Hepatol</source><year>2006</year><volume>45</volume><fpage>607</fpage><lpage>616</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2006.07.003</pub-id><pub-id pub-id-type="pmid">16901579</pub-id></mixed-citation></ref><ref id="CR39"><label>39.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pybus</surname><given-names>OG</given-names></name><name><surname>Cochrane</surname><given-names>A</given-names></name><name><surname>Holmes</surname><given-names>EC</given-names></name><etal/></person-group><article-title xml:lang="en">The hepatitis C virus epidemic among injecting drug users</article-title><source>Infect Genet Evol</source><year>2005</year><volume>5</volume><fpage>131</fpage><lpage>139</lpage><pub-id pub-id-type="doi">10.1016/j.meegid.2004.08.001</pub-id><pub-id pub-id-type="pmid">15639745</pub-id></mixed-citation></ref><ref id="CR40"><label>40.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robaeys</surname><given-names>G</given-names></name><name><surname>Bielen</surname><given-names>R</given-names></name><name><surname>Azar</surname><given-names>DG</given-names></name><etal/></person-group><article-title xml:lang="en">Global genotype distribution of hepatitis C viral infection among people who inject drugs</article-title><source>J Hepatol</source><year>2016</year><volume>65</volume><fpage>1094</fpage><lpage>1103</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2016.07.042</pub-id><pub-id pub-id-type="pmid">27520879</pub-id></mixed-citation></ref><ref id="CR41"><label>41.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Callegari-Jacques</surname><given-names>SM</given-names></name><name><surname>Grattapaglia</surname><given-names>D</given-names></name><name><surname>Salzano</surname><given-names>FM</given-names></name><etal/></person-group><article-title xml:lang="en">Historical genetics: spatiotemporal analysis of the formation of the Brazilian population</article-title><source>Am J Hum Biol</source><year>2003</year><volume>15</volume><fpage>824</fpage><lpage>834</lpage><pub-id pub-id-type="doi">10.1002/ajhb.10217</pub-id></mixed-citation></ref><ref id="CR42"><label>42.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grebely</surname><given-names>J</given-names></name><name><surname>Raffa</surname><given-names>JD</given-names></name><name><surname>Lai</surname><given-names>C</given-names></name><etal/></person-group><article-title xml:lang="en">Factors associated with spontaneous clearance of hepatitis C virus among illicit drug users</article-title><source>Can J Gastroenterol</source><year>2007</year><volume>21</volume><fpage>447</fpage><lpage>451</lpage><pub-id pub-id-type="doi">10.1155/2007/796325</pub-id></mixed-citation></ref><ref id="CR43"><label>43.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sá</surname><given-names>LC</given-names></name><name><surname>Araújo</surname><given-names>TM</given-names></name><name><surname>Griep</surname><given-names>RH</given-names></name><etal/></person-group><article-title xml:lang="en">Seroprevalence of hepatitis C and factors associated with this in crack users</article-title><source>Rev Lat Am Enfermagem</source><year>2013</year><volume>21</volume><fpage>1195</fpage><lpage>1202</lpage><pub-id pub-id-type="doi">10.1590/0104-1169.3126.2354</pub-id><pub-id pub-id-type="pmid">24402335</pub-id></mixed-citation></ref><ref id="CR44"><label>44.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aaron</surname><given-names>S</given-names></name><name><surname>McMahon</surname><given-names>JM</given-names></name><name><surname>Milano</surname><given-names>D</given-names></name><etal/></person-group><article-title xml:lang="en">Intranasal transmission of hepatitis C virus: virological and clinical evidence</article-title><source>Clin Infect Dis</source><year>2008</year><volume>47</volume><fpage>931</fpage><lpage>934</lpage><pub-id pub-id-type="doi">10.1086/591699</pub-id><pub-id pub-id-type="pmid">18764772</pub-id><pub-id pub-id-type="pmcid">6545569</pub-id></mixed-citation></ref><ref id="CR45"><label>45.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fischer</surname><given-names>B</given-names></name><name><surname>Powis</surname><given-names>J</given-names></name><name><surname>Firestone Cruz</surname><given-names>M</given-names></name><etal/></person-group><article-title xml:lang="en">Hepatitis C virus transmission among oral crack users: viral detection on crack paraphernalia</article-title><source>Eur J Gastroenterol Hepatol</source><year>2008</year><volume>20</volume><fpage>29</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1097/MEG.0b013e3282f16a8c</pub-id><pub-id pub-id-type="pmid">18090987</pub-id></mixed-citation></ref><ref id="CR46"><label>46.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Reis</surname><given-names>GKM</given-names></name><name><surname>Brito</surname><given-names>NAV</given-names></name><name><surname>Amaral</surname><given-names>CEM</given-names></name><etal/></person-group><article-title xml:lang="en">Detecção de ácido nucléico viral em equipamento para uso de crack: será que o vírus da hepatite C pode ser transmitido pelo uso compartilhado de cachimbos?</article-title><source>V Convibra - Gestão, Educação e Promoção da Saúde: Melhores Artigos (Portuguese Edition)</source><year>2017</year><comment>https://www.amazon.com/Convibra-Educa%C3%A7%C3%A3o-Promo%C3%A7%C3%A3o-Melhores-Portuguese-ebook/dp/B073D9FNKT. Accessed 3 Aug 2018</comment></mixed-citation></ref><ref id="CR47"><label>47.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thursz</surname><given-names>M</given-names></name><name><surname>Fontanet</surname><given-names>A</given-names></name></person-group><article-title xml:lang="en">HCV transmission in industrialized countries and resource-constrained areas</article-title><source>Nat Rev Gastroenterol Hepatol</source><year>2014</year><volume>11</volume><fpage>28</fpage><lpage>35</lpage><pub-id pub-id-type="coi">1:CAS:528:DC%2BC3sXhsFOltLbF</pub-id><pub-id pub-id-type="doi">10.1038/nrgastro.2013.179</pub-id><pub-id pub-id-type="pmid">24080775</pub-id></mixed-citation></ref><ref id="CR48"><label>48.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Urbanus</surname><given-names>AT</given-names></name><name><surname>van de Laar</surname><given-names>TJ</given-names></name><name><surname>Stolte</surname><given-names>IG</given-names></name><etal/></person-group><article-title xml:lang="en">Hepatitis C virus infections among HIV-infected men who have sex with men: an expanding epidemic</article-title><source>AIDS.</source><year>2009</year><volume>23</volume><fpage>F1</fpage><lpage>F7</lpage><pub-id pub-id-type="doi">10.1097/QAD.0b013e32832e5631</pub-id><pub-id pub-id-type="pmid">19542864</pub-id></mixed-citation></ref><ref id="CR49"><label>49.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hershow</surname><given-names>RC</given-names></name><name><surname>Kalish</surname><given-names>LA</given-names></name><name><surname>Sha</surname><given-names>B</given-names></name><etal/></person-group><article-title xml:lang="en">Hepatitis C virus infection in Chicago women with or at risk for HIV infection: evidence for sexual transmission</article-title><source>Sex Transm Dis</source><year>1998</year><volume>25</volume><fpage>527</fpage><lpage>532</lpage><pub-id pub-id-type="coi">1:STN:280:DyaK1M%2FnsVSmuw%3D%3D</pub-id><pub-id pub-id-type="doi">10.1097/00007435-199811000-00006</pub-id></mixed-citation></ref><ref id="CR50"><label>50.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marx</surname><given-names>MA</given-names></name><name><surname>Murugavel</surname><given-names>KG</given-names></name><name><surname>Tarwater</surname><given-names>PM</given-names></name><etal/></person-group><article-title xml:lang="en">Association of hepatitis c virus infection with sexual exposure in southern India</article-title><source>Clin Infect Dis</source><year>2003</year><volume>37</volume><fpage>514</fpage><lpage>520</lpage><pub-id pub-id-type="doi">10.1086/376639</pub-id><pub-id pub-id-type="pmid">12905135</pub-id></mixed-citation></ref><ref id="CR51"><label>51.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Sousa</surname><given-names>RAC</given-names></name><name><surname>Marques</surname><given-names>EM</given-names></name><name><surname>Frade</surname><given-names>PCR</given-names></name><etal/></person-group><article-title xml:lang="en">Syphilis among illicit drugs users in the state of Pará, Brazilian Amazon</article-title><source>Tropical Medicine</source><year>2017</year><comment>http://www.avidscience.com/wp-content/uploads/2017/08/syphilis-among-illicit-drugs-users-in-the-state-of-par%C3%A1-brazilian-amazon.pdf. Accessed 3 Aug 2018</comment></mixed-citation></ref></ref-list></ref-list><app-group><app id="App1"><sec id="Sec13"><title>Additional file</title><p id="Par44"><supplementary-material content-type="local-data" id="MOESM1" xlink:title="Additional file"><media xlink:href="MediaObjects/12879_2019_4270_MOESM1_ESM.docx" mimetype="application" mime-subtype="msword"><caption xml:lang="en"><p><bold>Figure S1.</bold> Sample of people who used illicit drugs accessed in each municipality in this study. <bold>Table S1.</bold> Univariate and multivariate analysis of factors not associated with HCV infection and HCV spontaneous clearance. (DOCX 49 kb)</p></caption></media></supplementary-material></p></sec></app></app-group><glossary><title>Abbreviations</title><def-list><def-item><term>95% CI</term><def><p id="Par5">95% Confidence interval</p></def></def-item><def-item><term>aOR</term><def><p id="Par6">Adjusted Odds Ratio</p></def></def-item><def-item><term>cDNA</term><def><p id="Par7">Complementary DNA</p></def></def-item><def-item><term>EIA</term><def><p id="Par8">Enzyme immunoassay</p></def></def-item><def-item><term>HCV</term><def><p id="Par9">Hepatitis C virus</p></def></def-item><def-item><term>HSC</term><def><p id="Par10">HCV spontaneous clearance</p></def></def-item><def-item><term>OR</term><def><p id="Par11">Odds Ratio</p></def></def-item><def-item><term>PCR</term><def><p id="Par12">Polymerase chain reaction</p></def></def-item><def-item><term>PWUIDs</term><def><p id="Par13">People who used illicit drugs</p></def></def-item><def-item><term>RIBA</term><def><p id="Par14">Immuno Blot Assay</p></def></def-item><def-item><term>RNA</term><def><p id="Par15">Ribonucleic Acid</p></def></def-item><def-item><term>UFPA</term><def><p id="Par16">Universidade Federal do Pará</p></def></def-item><def-item><term>UNIFAP</term><def><p id="Par17">Universidade Federal do Amapá</p></def></def-item><def-item><term>UTR</term><def><p id="Par18">Untranslated region</p></def></def-item></def-list></glossary><notes notes-type="Misc"><title>Publisher’s Note</title><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></notes></back></article></records><facets><facet name="subject"><facet-value count="1">Infectious Diseases</facet-value><facet-value count="1">Internal Medicine</facet-value><facet-value count="1">Medical Microbiology</facet-value><facet-value count="1">Medicine &amp; Public Health</facet-value><facet-value count="1">Parasitology</facet-value><facet-value count="1">Tropical Medicine</facet-value></facet><facet name="keyword"><facet-value count="1">Amazon</facet-value><facet-value count="1">Brazil</facet-value><facet-value count="1">Epidemiology</facet-value><facet-value count="1">HCV</facet-value><facet-value count="1">People who used illicit drugs</facet-value><facet-value count="1">Spontaneous clearance</facet-value></facet><facet name="pub"><facet-value count="1">BMC Infectious Diseases</facet-value></facet><facet name="year"><facet-value count="1">2019</facet-value></facet><facet name="country"><facet-value count="1">Brazil</facet-value><facet-value count="1">Canada</facet-value><facet-value count="1">New Zealand</facet-value></facet><facet name="type"><facet-value count="1">Journal</facet-value></facet></facets></response>
